| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  uniQure Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease 160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 334 |
 | TAGC Understanding biological complexity, from genotype to phenotype, with interdisciplinary approaches. Our laboratory is a joint research unit of INSERM and the University of Aix-Marseille. We seek to decipher the complex biological mechanisms involved in the development or physiological functioning of an organism. Our research project is organized around two axes, one entitled "bioinformatics and genomics of molecular networks", the second "genetics and genomics of multifactorial diseases". We conduct not only basic research projects, but also collaborative projects with hospitals and biotech companies. This policy is fully in line with INSERM's strategic plan. Our ambition is both to contribute to a … 27 similar entities Type: SMB Activities: deeptech Technologies: Synthetic Biology | 1 | 16 |
 | PhysioStim Nonclinical expert in cardiovascular pharmacology & electrophysiology and vascular functions PhysioStim is a French preclinical CRO dedicated to cardiovascular pharmacology and electrophysiology from discovery stages to clinical development. Whatever the therapeutic areas, we ensure robust and valuable preclinical data on cardiac and vascular activities and secondary pharmacology to secure in-vivo development and bring new safe therapies to patients. Thanks to our predictive and translational models, we define the POC of drug discovery, we investigate secondary pharmacology with on and off-target liabilities, and we address the safety purpose to build and support your IND submission (with mandatory and not mandatory assays). … 41 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 11 |
 | En Carta Diagnostics Diagnostics for better care, everywhere. Diagnostics for Better care, Everywhere. En Carta Diagnostics is a synthetic-biology biotech company leveraging patented technologies to decentralise highly reliable molecular diagnostic solutions. synthetic biology, cell-free, biotech, and molecular sensing 60 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 5 | 12 |
 |  DeepLife AI for digital twin of cells DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, … 91 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Deep Learning SaaS | 27 | 30 |
 | TransCure bioServices Leading CRO in preclinical research with cutting-edge humanized mouse models for drug development. Rethinking preclinical research - with your goals in mind. TransCure bioServices accelerates drug development by delivering the right models, the right data, with the right partnership mindset. Our advanced humanized mouse models provide robust, translational in vivo results to guide decision-making in: • Oncology (Human CDX, Human PDX, Syngeneic Models) • Inflammatory diseases (IBD, MASH, GvHD, Lung Inflammation) • Infectious diseases & toxicity (HIV, HBV, Immunotoxicity, Hepatotoxicity) You know your drug. We know how to test it. Every study is co-designed with your team to fit your … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics | 4 | 74 |
 | Inoviem Scientific Creative Technologies for Efficient Therapeutics, Precision medicine Inoviem Scientific is a private Bioanalytical company which delivers enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. We reconcile translational pharmacology and human physiology by using fresh patient material from the target cohort, embracing the complexity of human diseases. Inoviem's enabling technologies are working in pathological conditions to get the treatment in development to the right patient. Our indication-agnostic access to patients combined with innovative label-free platforms deliver Target identification and validation, targets & Mode of Action deconvolution, patient stratification, … 84 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 8 |
 | Guilford Street Laboratories At Guilford Street Laboratories (GSL), a UCL spin-out, we are dedicated to helping our clients achieve their research objectives. Leveraging machine learning-driven mass spectrometry, we deliver highly precise and sensitive biomarker panels, specializing in the analysis of protein, lipid, and metabolite markers. Whether your focus is on early disease diagnosis, drug discovery, collaboration as a partner in an EU Horizon consortium, clinical trials, or personalized medicine, our team is here to help. Mass Spectrometry, Biomarker, CRO, and Rare Disease 25 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. - Machine Learning Data Analytics | 0 | 11 |
 | Inoviv Accelerating the Development of New Medicines with Targeted Proteomics Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development. Proteomics, Biomarker Discovery, Translational Biomarkers, Mass Spectrometry, Targeted Proteomics, Discovery Proteomics, Biomarkers, Precision Medicine, Proteomic Analysis, Proteome Profiling , Quantitative Proteomics, Liquid Chromatography Mass-Spectrometry (LC-MS), Post-Translational Modifications (PTMs), Quantitative Biomarkers, Clinical Proteomics, Immuno-Precipitation Mass Spectrometry (IP-MS), Proteins, LC-MS Proteomics, Proteomics Services, and Protein Identification 165 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology | 0 | 31 |
 | GeneHub Empowering patients to bridge rare disease research and trials through a revolutionary clinico-genomic databank. Backed by VCs and an IUK government grant, GeneHub is building the world's first patient-controlled, clinico-genomic databank to bridge rare disease research and clinical trials. GeneHub enhances patient visibility and engagement by elevating patients into verified, zero-party data partners equipped with longitudinal real-world data from primary and secondary care. To ensure privacy, patients must consent to researchers analysing their anonymised clinico-genomic data in secure, on-demand, clean rooms. Patients actively engaging with researchers benefit from free advanced diagnostics such as DNA and mRNA sequencing, accelerating clinical trial … 12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 6 |
 |  Pharm'image #Pharmaco-imaging, #nuclear medicine, #PET/MRI, #Radiochemistry, #Preclinical models Created in 2008 in Dijon, Pharm’image is a regional center of excellence in Pharmaco-imaging. Unique in France, it brings together hospitals, biotechnology, and pharmaceutical companies, to offer state-of-the-art of functional and molecular imaging technologies (MRI, PET, SPECT, CT), ranging from small-animal scale for preclinical experimentation to clinical exploitation Its aim is to deploy cutting-edge medical imaging technologies to evaluate biomarkers that can be used to track treatment efficacy and select the active and most promising drug candidates. imaging, preclinical evaluation, pharmacology, molecular imaging, nuclear medicine, radiochemistry, bioconjugation, translational research, in vivo pharmaco-imaging, First … 59 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | Okomera Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity 333 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 42 | 30 |
 | Rime Bioinformatics Making high performance bioinformatics accessible. Rime Bioinformatics is a research and development biotechnology company with a focus on bioinformatics. We develop services to speed up medical, agronomic and veterinary research. Our technologies grant in-depth view of bacterial and bacteriophage genomes, which is an essential prerequisite in the R&D process that leads a phage to market. We work hard to make high-performance bioinformatics accessible and promote a safe use of phage therapy for the patients and the environment ! Bioinformatics, Phage, Bacteriophage, Genomics, Bacteria, Phage Therapy, and metagenomics 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 4 |
 | GENEIX We personalise prescribing by matching medication to patient data and DNA. Empowering doctors to say 'this drug is not for everyone, but it is for you. Founded in 2012, we are a London based start-up committed to personalising medicine. To achieve this, we've built a strong team with extensive expertise in pharmacogenetics, pharmacology, big data analytics, business strategy, the NHS and creative design. Pharmacogenetics, Personalised Medicine, Bioinformatics, CPOE, Big Data, and Design 78 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Data Analytics | 3 | 0 |
 |  Galactica Biotech Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications 290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 0 | 1 |
 | CytoReason The First Cell-Centered Computational Model of Human Disease CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain … 79 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 9 | 131 |
 | PhiTech Bioinformatics More Omics into Clinics Pioneering the integration of DNA & RNA sequencing data with AI for rare disease diagnostics Follow us on Twitter @PhiTech_Bioinfo Bioinformatics, Genomics, Transcriptomics, Epigenomics, AI, and Rare Diseases 135 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics | 1 | 27 |
 | Synbio Technologies Changing the world, one sequence at a time. Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology … 76 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology | 1 | 23 |
 | Ncardia Ncardia believes that human stem cell (iPSCs) technologies will bring better therapies to patients faster. Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with biopharmaceutical companies in drug discovery worldwide, to leverage the power of stem cell technologies in the development of novel therapies of multiple modalities at any stage of development. Over the past 10 years, we have built the expertise and infrastructure required to differentiate, manufacture and characterize high-quality iPSC-derived cell and disease models. We can facilitate the process … 62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 56 |
 | Monument Therapeutics Bringing Precision Medicine to Neuroscience Drug Development Monument Tx is an independent UK based biotechnology company formed as a spin-out from Cambridge Cognition in 2021. Monument Tx develops products to treat serious diseases of the central nervous system. Our precision medicine approach utilises proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, which are then matched with appropriately targeted compounds. Using biomarkers to more accurately identify patients with a disease sub-type most likely to respond to a particular treatment is already successfully used in the treatment of cancer. Now Monument Tx brings digital biomarkers to neuroscience … 26 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 8 |
 | Predictiv Care 🧬 DNA-based Digital Twin to help predict and prevent diseases and adverse reaction to drugs Personal genomics solution for predictive medicine—Thanks to unique and groundbreaking technology, Predictiv identifies the genetic predispositions of an individual on 22,000+ diseases and simulated reactions to 750+ drugs. Now enabling more accurate preventive actions and treatments. genomics, predictive medicine, preventive medicine, heathcare, and biotechnology 67 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 18 | 8 |
 | Life Length Measuring life for the world Founded in 2010, Life Length stands out as a global leader in diagnostic biotechnology, specializing in telomere diagnostics. Our proprietary platform technology, TAT®, is based on the measurement of telomere variables and assays related to aging and age-related diseases. This patented technique allows quantification of telomere length at the individual cell level and is applicable to blood, cell culture and tissue samples. Recently, we have developed a biomarker for the early detection of prostate cancer with this technology. This biomarker is authorized by the AEMPS in Europe and by the CMS in the United States, … 16 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 47 |
 | Concr Solving data to enable precision therapy for all Concr is a techbio company providing predictive modelling solutions to enhance confidence and foresight about therapeutic efficacy of existing and emerging cancer drugs. By accurately predicting response for individual patients and cohorts, we enable more efficacious and informative trials, thereby improving probability of success of novel cancer therapeutics. Our Farr-Sight® platform, built on decades of astrophysics research, models diverse data interactions to simulate human disease biology, enabling accurate predictions with minimal data. This is especially valuable in early-stage trials and rare cancers. Validated through collaborations with Roche, Step Pharma, The Institute of … 62 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I. | 9 | 9 |
 | PepGen Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics 436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 82 |
 | Lantern Pharma Inc. (Nasdaq: LTRN) Leveraging Artificial Intelligence to Rescue and Develop Cancer Therapies Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials. Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR … 64 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 1 | 27 |
 | Biomaneo, a Shimadzu group company A Shimadzu Group Company Bimaneo specializes in the design and marketing of innovative medical analysis kits based on the fine analysis of mass spectrometry proteins for neonatal screening and the diagnosis of various pathologies in hospital laboratories. Screening and diagnosis, mass spectrometry, medical device, and biological markers 158 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology | 0 | 6 |
 | METAFORA biosystems AI-Powered Cytometry & Cell Metabolism Profiling At Metafora, we develop innovative and impactful AI-powered cytometry & cell metabolism profiling solutions. We are passionate about cell biology. We leverage our unique cell metabolism and AI-powered data analysis platforms to turn disruptive single-cell technologies into impactful solutions that improve human health. biomarkeurs, cell metabolism, flow cytometry, data analysis, biotechnology, IVD tests, diagnostics, diagnostic tests, cell biology, neurometabolic diseases, metabolic diseases, oncology, multiple myeloma, and research 82 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 23 | 36 |
 | NEBULA Transforming Drug Target Discovery with Physics-Based dataset-free genAI Partnerships At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I. | 10 | 5 |
 | MEDIBIOFARMA SL To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies 540 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 9 |
 | PsychoGenics Discover Your Next Breakthrough PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into … 40 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 180 |
 | Cerba Research Transforming Research, Advancing Health Together At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation … 76 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Data Analytics Synthetic Biology | 5 | 619 |
 | Hybrigenics Services Expert in target deconvolution for drugs, protein-protein interactions and single-domain antibodies Who else knows your drug or protein better than you? Who else knows protein interactions better than us? Hybrigenics Services is a complete solution provider of cutting-edge technologies dedicated to the study of protein interactions and target identification for drugs. We are also proud to now offer a unique, proprietary nanobody selection service. We help researchers: - Understand proteins' functions through the elucidation of their interactions - Characterize precisely a known interaction (map critical domains or amino-acids...) - Identify the targets of small molecules of therapeutic interest - Predict … 37 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 33 |
 | One Biosciences Focused on generating precision medicines by leveraging the power of single-cell technologies One Biosciences leverages the power of single-cell analysis to unlock a new wave of targets and precision medicines for a broad range of difficult-to-treat conditions. One Biosciences is an integrated discovery engine combining a multi-disciplinary team with in-house computational capabilities. One Biosciences is backed by Institut Curie and Home Biosciences. 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 12 | 22 |
 | SYNAXYS Accelerate drug development for neurological diseases SYNAXYS is French biotech specialized in the characterization of the response of the nervous system for nutraceutic, pharmaceutic and veterinary applications. We offer a complete range of R&D services to support drug development, from defining the dose effects in a human model, to identify biological targets and action mechanism, acute and chronic toxicity, or comparison to established treatments. Our field of application: - Drug positioning - Therapeutic evaluation in a diease model - Neuro-oncology - Data generation for IA modeling Neuro-engineering, Neuronal diseases modeling, Neuro-oncology, Autism, Alzheimer disease, and Glioblastoma 101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 2 |
 | LifeNome Inc. Precision Health and Genomics AI Platform LifeNome is a precision (biology-personalized) health platform powered by Genomics AI (c). We leverage systems-biology, multi-omics, and proprietary artificial intelligence to personalize health and wellbeing services and products of healthcare, insurance, pharmaceutical, nutrition, and fitness organizations worldwide. Our focus areas include precision preventive health (disease screening and intervention design), precision maternal and family health, and precision nutrition, and wellbeing. Awards and Recognitions: - LG Select 10 ($2 Million) - PEPSICO $100K Top Prize Food Tech Accelerator - Best Enterprise Precision Health and Wellness Platform (Biotech Awards, 2021) - Top Personalized Health Startup (Lux Research, … 60 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. | 17 | 16 |
 | CardiaTec Bio Decoding cardiovascular disease biology for novel therapeutic discovery CardiaTec is a TechBio company employing computational methods to decode the biology behind cardiovascular disease. The company leverages human multiomics data to better navigate complex disease biology to identify novel and differentiated therapeutics. CardiaTec is building the first and largest proprietary human heart tissue multiomics dataset. The company has a large and growing network of over 65 hospitals across the US and the UK, screening patients on a 24/7 basis to support the bespoke collection of human cardiac tissues. The company spun out of the Han Lab at the University of Cambridge … 88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 9 | 14 |
 | Cytochroma Accelerating global drug development Cytochroma predict how drugs will react in a global population in health or disease. Our unique, ethnically diverse library of iPSC and automated cell culture generates robust, reliable, mature hepatocytes for toxicity testing. We are supporting life science companies, de-risking safe compounds prior to clinical testing, making new drug development faster, safer and more efficient. toxicity testing, liver specialists, hepatocyte testing, disease models, high throughput, high content screening, iPSC, automated manufacture, machine learning, artificial intelligence, predictive testing, and pre clinical testing 133 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 2 | 4 |
 | AnyGenes® Since more than 10 years, AnyGenes® scientists develop and produce innovative high throughput screening products for signaling pathway analysis. These kits and reagents allow high throughput transcriptomic analysis of a large collection of signaling pathways in many species, biomarkers identification and validation, as well as validation of microarrays results. AnyGenes®, with its innovative & cost effective technologies, products and its proprietary molecular platform, helps scientists to accelerate their projects, publications, and biotech companies for drug development and biomarkers validation. Located in Paris, within Tenon Hospital in the 20th arrondissement, AnyGenes® constitutes a key player in the Biotechnology field. Supported by … 21 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 5 |
 | LXRepair 2013-2023 2013-2023 In a context where the rate of cancer treatment failure is still unacceptably high, our mission is to provide decision aids to oncologists. We believe that profiling is key to predicting treatment toxicity to patients and effectiveness on tumors. Over a decade of research by the French Atomic Energy Commission (CEA) on the impact of radiations on DNA has resulted in a deep understanding of the essential DNA repair mechanisms. More recently, a set of innovative biomarkers was developed that provides a complete functional signature of these mechanisms, the premise to powerful tools for personalized treatment of cancer. http://www.lxrepair.com … 66 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 3 |
 | Depixus Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies. Single molecule analysis, RNA Drug Discovery, Protein-protein Interaction Analysis, Biophysics, Drug Discovery, Compound Screening, biomolecular interactions, and interactomics 159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 57 |
 | genedrive Advancing Diagnostics to the Point Of Care Genedrive Diagnostics Ltd is a pharmacogenetic testing company developing and commercialising a rapid and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 … 9 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 47 |
 | Luxia Scientific New generation microbiome diagnostics for personalised medicine Luxia Scientific is a french start-up company, leading the next wave of breakthrough personalized diagnostics. The company was started by Alessandra Cervino, former research director at Enterome. Luxia scientific is pioneering the development of novel diagnostics based on the genetic analysis of microbiomes. The company has brought to the market it’s first test in Q4 2018 and is developing two additional diagnostics. The Company is affiliated to Medicen and is supported by the BPI, Region Ile de France. Statistics, Biomarkers, Statistical genetics, qPCR, genetics, genomics, microbiome, metagenomics, nutrition, well being, health, probiotics, prebiotics, … 60 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Data Analytics Synthetic Biology | 4 | 1 |
 | MedInsights Reimagining drug repositioning At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from rare diseases. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, and Healthcare 133 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics | 29 | 4 |
 | Diagante Unlocking the potential of solid samples in the field of biological diagnostic Diagante develops a solution for in vitro diagnostics. Its platform allows the analysis of solid clinical specimen on rapid and high throughput instruments in clinical pathology labs. It provides faster results, enhanced personalized medical care, and lower costs to the stakeholders. 75 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology | 23 | 7 |
 | Genvade Therapeutics Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne 101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | N/A |
 | GD Biotech GD Biotech is a spin-off of the Gènes Diffusion group that has a portfolio of biotechnologies and bioinformatics tools. GD Biotech, a spin-off of the Gènes Diffusion group (a leading European player in the field of genetics and animal reproduction), relies on a multidisciplinary team of biologists and bioinformaticians to assist you in the analysis of your samples. Because observable traits of living organisms are the result of genetic potential in a given context, our solutions cover DNA analysis (genotyping), biomarker detection (multiplex ELISA) and environmental characterization (microbiota). GD Biotech operates in the agricultural, food and environmental sectors. Our analysis … 45 similar entities Type: Startup Activities: deeptech Technologies: Data Analytics | 9 | 12 |
 | AUM Biosciences Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules 550 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 18 |
 | MOBILion Systems, Inc. The MOBILion team is focused on developing instruments that improve how we predict, diagnose and treat disease. MOBILion’s technology makes it easy to separate, identify and analyze the most challenging molecules that other instruments fail to detect. Our higher resolution, faster analysis and simpler workflows reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. We make today’s treatment’s safer and more effective, empower tomorrow’s disease prediction and diagnosis, and accelerate the development of new therapies. 81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 48 |
 | BiogeniQ BiogeniQ helps people optimize their nutrition and medication based on their genetic composition. We allow everyone to access important portions of their DNA, while providing a useful tool for healthcare professionals. We put emphasis on solid, peer-reviewed research and integration of our genetic reports into future healthcare. Médecine Personnalisée, Dépistage Génétique, Nutrigénomique, Pharmacogénétique, Génotypage, and Génomique 23 similar entities Type: Startup Activities: biotech deeptech | 5 | 2 |
 | Parean Biotechnologies Deep Immune Phenotyping & MultiOmics DataScience, for immune precision medicine Parean Biotechnologies is a next generation service company dedicated to advancing preclinical and clinical programs in the field of oncology and immune related diseases. Our comprehensive approach integrates an in-house wet lab (cytometry, cell sorting, libraries generation in bulk or single cell protocols) and a omics biostatistics unit to drive innovation and foster transformative breakthroughs. Key offerings includes: -Wet Labs: unparalleled proficiency in deep immune phenotyping and tumor cells, with a focus on T-Cell, B-Cell, NK, and other immune cell subsets. - End-to-End Immune Cells Analysis: comprehensive immune cells analysis … 18 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics | 10 | 8 |
 | Icosagen European Mammalian CRDMO - From Discovery mgs to Clinical GMP kgs. We're a leading European biotechnology company, providing streamlined or custom-tailored services for global clients in pharmaceutical, biotechnology industries, and academia. We've been a privately held family business since 1999, and have grown into a leading mammalian Contract Research, Development, and Manufacturing Organization (CRDMO). The CRDMO approach allows us to cover the entire spectrum of pre-clinical and clinical services - from the initial stages of target discovery and development, to cell line development, and manufacturing of mammalian therapeutic proteins, up to 1000 L scale. In 2023, we worked with more … 136 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 148 |
 | MI:RNA Diagnostics Veterinary diagnostic testing evolution, innovation, research and solutions MI:RNA Diagnostics have developed a novel early disease detection technology for the veterinary market that uses microRNA biomarkers to accurately identify if disease is present, through blood sample analysis. By combining this method with an artificial intelligence learning model to enable interpretation, they have adopted a true precision medicine approach. Paving the way, they hope, for many other innovative solutions in this field. It is their mission to reduce disease through research and innovation, resulting in a cascade of ethical, environmental, and economic benefits. 60 similar entities Type: SMB Activities: pettech deeptech biotech Technologies: Data Analytics Synthetic Biology | 5 | 25 |
 | MiNA Therapeutics Activating RNA, mastering disease Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients’ cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver and other diseases. Gene activation, RNA therapeutics, Liver disease, and Drug discovery 213 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 33 |
 | QuantuMDx Transforming Point of Need Multiplex Diagnostics QuantuMDx is a progressive MedTech company passionate about creating multiplex molecular diagnostic solutions for use at the point of need. MedTech, Molecular Diagnostics, Multiplex Molecular Diagnostics, Point of Care, Point of Need, COVID-19, Medical device, Diagnostic device, DNA extraction, TB, Sepsis, Transcriptomics, PCR, Microarray, Assay Development, Assay Feasibility, Rapid Diagnostics, Respiratory Infections, Sexually Transmitted Infections, Host Response, and In vitro Diagnostics 154 similar entities Type: Startup Activities: deeptech biotech healthtech nanotech Technologies: Synthetic Biology | 8 | 86 |
 | Cellomatics Biosciences Ltd Our expertise, Your discovery Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas. Based at Colwick Quays Business Park, Nottingham UK, our experienced scientific team offers bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Multiplex Immunoassay, Target and biomarker validation, In vitro functional assays, Molecular Biology, Receptor binding, Toxicity testing, Immuno-Oncology, Oncology, Immunology, Inflammation, and Respiratory 376 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 1 | 19 |
 | Intelliseq Master Genomic Analysis: User-Friendly, Adaptable & Comprehensive solution for Professionals Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility. bioinformatics, next generation sequencing, biotechnology, diagnostics, and genetics 45 similar entities Type: Startup Activities: deeptech Technologies: Data Analytics | 8 | 16 |
 | NuMedii NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. 64 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics | 2 | 5 |
 | Voyager Therapeutics, Inc. Leveraging genetics to treat neurological diseases Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACERTM AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs … 71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 190 |
 | TRON-Mainz Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics … 126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 188 |
 | AOA Dx Transforming Women’s Health with Breakthrough Cancer Diagnostics and AI AOA Dx is leading a revolutionary breakthrough in early-stage cancer detection for women, leveraging the transformative potential of AI and our proprietary biomarker technology. At the heart of this innovation is our GlycoLocate platform, a multi-omics approach powered by tumor marker gangliosides, lipids and proteins. This platform is setting a new gold standard in the quest for life-saving early cancer diagnostics. We are now advancing AKRIVIS GDTM, a cutting-edge liquid biopsy test designed specifically for the early detection of ovarian cancer. Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, … 57 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 7 | 54 |
 | GENZ Biotechnology Developing novel IVD solutions Genz is a spin-off biotech company developing novel solutions from in vitro diagnostics to therapeutics. Our mission is to deliver a consistent stream of innovative, affordable, and accessible diagnostic solutions and make a remarkable impact on people’s lives. We’re focused on sustainable growth and addressing the world’s pressing health challenges; therefore, we’re able to create value for both our patients and our shareholders. To date, Genz developed 4 IVD diagnostic tests commercially legalized, attended International joint projects, partnered with top research centers in the world and published several scientific articles in international scientific journals. Biotechnology, Genetik … 161 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 0 | 2 |
 | ViroScan3D Solutions Personnalisées de Génomique ViroScan3D is a service provider in genomic and micro-genomic located in Lyon. We have ten year experience in genome scale analyses from sample preparation to data analysis. During those years we have developed specific processes dedicated to complex samples (low quality and quantity samples). We propose our services for -Molecular broad spectrum identification of infectious agents, new agents, resistance mutants by whole genome sequencing of viruses and microorganisms (bacteria, yeast, fungi, etc.) -Analysis of complex populations using the metagenome, virome, bacteriome approach to identify the different agents in the population and their proportions -The identification of … 8 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics Synthetic Biology | 0 | 2 |
 | NeoVentures Biotechnology Europe Aptamarker Platform | High-Plex Proteomics | Biomarker Discovery | Advanced DNA Aptamer Library & Machine Learning At NeoVentures Biotechnology Europe we are committed to revolutionizing the biopharmaceutical field through a cutting-edge biomarker discovery platform, propelling the industry towards personalized medicine with rapid, cost-effective, and automated processes for biomarker discovery and validation. Our Aptamarker platform leverages a library of 16.8 million DNA aptamers to analyze epitope profiles in biofluids, liquid biopsy or tissue, facilitating the precise measurement of surrogate biomarkers and expediting the creation of predictive In Vitro Diagnostic (IVD) tests tailored to distinct pathophysiological conditions. With our advanced DNA aptamer … 16 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 4 | 4 |
 | KCAS Bio - Lyon Science Accelerated KCAS Bio - Lyon (Active Biomarkers) operates as a bioanalytical laboratory based in Lyon, France and headquartered in Olathe, Kansas, USA. We offer comprehensive service solutions for the development of both large and small molecules, with extensive capabilities and expertise in pharmacokinetics, immunogenicity, soluble and cellular biomarker analysis for clinical trials. Operating in state-of-the-art BSL2 facilities, our company is GLP certified and ISO 9001:2015 certified, with a unique track-record in the development, validation, and implementation of analytical methods. Our expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. … 57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology Data Analytics | 2 | 31 |
 | GeneAdviser Genetics is advancing at a rapid pace, transforming research and revolutionising the way we diagnose and treat complex diseases such as heart disease and cancer. We are a team of scientists and developers specialised in genetics and bioinformatics, determined to increase access to genomic medicine in the clinic. We develop innovative solutions to make genomic medicine more accessible, partnering with a portfolio of private and public laboratories in the UK and overseas. Our approach is strongly shaped by our scientific background and experience. Our flexible, powerful online ordering platform for genetic tests enables clinicians to find and order tests for … Type: Startup Activities: biotech deeptech Technologies: SaaS | 0 | 0 |
 | Nimbus Therapeutics We develop breakthrough medicines for patients through precision small molecule design. Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus' pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases. … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 10 | 108 |
 | Rosetta Omics Unlocking the road to precision medicine by tumor characterization via high resolution proteomic profiling. Worldwide, there are more than 20 million new cases of cancer each year. First-line therapies are not always the most effective and there is a strong need to move towards personalized medicine by offering the patients the best treatment as quickly as possible. This will help in increasing the chance or cure. Therefore, there is a need to improve the prediction of the response to treatments to be able to save patient’s lives and reduce the cost of expensive inefficient treatments. Our goal is to unlock … Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 20 | 10 |
 | Cell Environment Cyto-genomic technology to measure chromosomal health Cell Environment is a company created in 2016 that developed a new automated cyto-genomic approach combining new cytogenetics techniques with molecular genetics, based on 20 years of academic and private research. It allows to precisely analyse repetitive sequences (50% of the genome) as telomeres & centromeres and detect other chromosomal aberrations. This technology can be applied to better stratify populations for precision medicine in oncology for instance, to help diagnose some conditions as infertility or prenatal conditions, to measure toxic effects of certain treatments (in oncology) or of radiations, to measure the quality of … Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 11 | 12 |
 | Ksilink Patient-based drug discovery We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine. AI image and data analysis, biology, high content screening, high throughput screening, deep learning, assay development, patient stratification, pyschiatric disorders, and cardiac muscle 235 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: A.I. Synthetic Biology | 4 | 20 |
 | Firalis Molecular Precision CRO & CDMO | Streamlining your Drug Development Process, paving the way for a more Personalized Medicine. Firalis Molecular Precision (FMP) is a fast-growing CRO & CDMO, providing advanced and tailored BioAnalytical Testing services to the Life Sciences sector, based in Huningue, France and in Cambridge, USA. FMP's team leverages its extensive scientific expertise and cutting-edge in-house platforms to provide a range of services, namely sample storage and management, bioanalytical testing, omic data analysis and interpretation, assay development and production - delivering high-quality data to support you along the entire drug development process. FMP's mission is to provide healthcare professionals, … Type: Startup Activities: deeptech biotech Technologies: Data Analytics | 1 | 32 |
 | Lexicon Pharmaceuticals, Inc. At Lexicon, We Pioneer Medicines that Transform Patients' Lives Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies … 64 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 321 |
 | Physiogenex Leading preclinical CRO specializing in metabolic disorders. Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions … 63 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 4 | 24 |
 | Quanterix Discovery Fueled by Ultra-Sensitivity Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research … 92 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 16 | 430 |
 | MEDGENOME Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Our powerful genomics solutions accelerate biomarker identification and discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome Inc. has its Corporate Headquarters and a Next Generation Sequencing (NGS) lab in Foster City, California, US. MedGenome Labs is … 41 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology | 6 | 870 |
 | AYOXXA Biosystems GmbH AYOXXA – the Translational Proteomics Company. Understanding complex biology from bench to bedside. AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARISTM. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARISTM is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics … 12 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 23 |
 | Genomic Expression Inc The RNA Platform - by analyzing RNA we can detect disease, monitor health and design the Next Generation Cures Today only 1 out if 4 cancer drugs prolongs life because we treat all the patients the same way. Genomic Expression’s OneRNATM test can save lives and make healthcare delivery more effective by sequencing RNA and linking RNA’s to approved therapies and clinical trials. Genomics, information, personalized medicine, personalized diagnostics, Sequencing, prognostics, bioinformatics, sample preparation, Next Generation Sequencing, Biobank, Access to biological samples, target filtering, RNA-seq, RNA sequencing, and RNASeq of FFPE samples 102 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 10 |
 | Multiomic Health AI-Enabled Precision Medicine for Metabolic Syndrome-Related Conditions Multiomic Health is a data-centric therapeutics venture, writing the latest chapter of the precision medicine story by tackling a global, trillion dollar healthcare problem: metabolic syndrome-related conditions (atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease and non-alcoholic fatty liver). Our mission is to transform patient health outcomes with precision medicines that go beyond the one-size-fits-all approach currently dominating this disease space. We apply advanced computational systems biology modelling and AI-enabled predictive analytics on deep, standardised patient datasets. These datasets feed into a data lake of thousands of patients, featuring millions of data … 12 similar entities Type: Startup Activities: deeptech Technologies: A.I. | 4 | 21 |
 | oncgnostics GmbH Precision in Cancer Diagnostics oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics. Diagnostik, Epigenetik, Medizin, Assay Development, Diagnostics, DNA-Methylation, Medicine, and LifeScience Developments 123 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology | 1 | 33 |
 | FenoMark Diagnostics AB The best cancer treatment for all with robust, reliable and data rich proteomics on routinely biobanked FFPE tissue Dedicated to improving cancer care by developing better diagnostic assays for therapy selection. diagnostics, cancer, proteomics, biomarkers, mass spectrometry, tissue, clinical, and quality 30 similar entities Type: Startup Activities: biotech deeptech | 1 | 4 |
 | GENOSKIN Redefining Non-Clinical Research with Live Human Skin Genoskin offers unmatched expertise in skin biology and immunology to support your research and drug development. Our mission is to generate reliable human data before regulatory studies for therapeutics, vaccines, medical devices, cosmetics, and chemicals. Using donated human skin, we preserve its viability for up to seven days post-surgery with our proprietary patented technology—allowing comprehensive testing across all cell types and skin structures. Unlike animal or engineered models, our platforms provide authentic, human-relevant data. With advanced assays, including imaging techniques and next-generation sequencing, combined with deep scientific expertise, we equip you with the … 61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 19 | 46 |
 | ReviveMed AI-based Metabolic Platform for Precision Medicine ReviveMed, an MIT spinout, is an AI-driven metabolomics platform for precision medicine. Our patented technology detects 20x more metabolites per patient than traditional methods, enabling the creation of digital metabolic twins. Digital metabolic twins are virtual patient models representing individuals’ metabolic networks within a multi-omic context to simulate health and disease. We have a pipeline of metabolic twins for oncology and cardio-metabolic diseases, such as renal cell carcinoma, MASH, and obesity. Our metabolic twins increase trial success rates by predicting which patients respond to drugs and reducing trial sizes by simulating disease progression in … Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology | 3 | 7 |
 | NGM Biopharmaceuticals Explorers on the frontier of life-changing science. NGM Bio is a biopharmaceutical company focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates … 59 similar entities Type: Startup Activities: biotech manufacturing deeptech Technologies: Synthetic Biology | 2 | 135 |
 | Ranomics Ranomics offers innovative solutions for protein engineering, drug discovery, genomics research and synthetic biology Ranomics offers high throughput solutions for protein engineering, drug discovery, genomics research and synthetic biology. Using our VariantFind and VERG genomics platforms, Ranomics offers partners the a scalable solution to engineer and screen genetic variants in a wide range of model organisms. Our industry leading DNA Variant libraries and high-throughput cell assays help researchers to hit their research objectives faster and with better results than traditional methods. Over the years, we have worked with top biotech and pharma companies in the US and worldwide. Our partners … 186 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 7 |
 | Genomic Vision Genomic Vision is a French biotech providing tools and services to visualize and characterize single DNA molecules. GENOMIC VISION develops novel diagnostic and drug discovery solutions based on its world-leading nanotechnology for DNA analysis in the areas of cancer and acute diseases. These diagnostic tests and drug discovery tools operate where genome dynamics and human disease intersect. GENOMIC VISION uses a powerful technique, Molecular Combing Technology, for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. GENOMIC VISION initial focus is towards early cancer detection and … Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 15 |
 | Biosortia, Inc. Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover … 69 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning | 1 | 10 |
 | Mainz Biomed Saving lives through innovative molecular diagnostic solutions. Mainz Biomed is aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere. We develop innovative products that quickly and easily identify the early onset of several leading deadly conditions including colorectal and pancreatic cancers. Visit our website www.mainzbiomed.com to learn more about our company and our mission to save lives through science. molecular genetic in-vitro diagnostics 25 similar entities Type: Startup Activities: deeptech biotech | 1 | 35 |
 | Ethris Clinical stage biotech company focused on development of disruptive mRNA therapeutics for severe respiratory diseases Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners. Biotechnology, mRNA, LNPs, Vaccines, Therapeutics, Formulation, and Manufacturing 87 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 0 | 52 |
 | Calico Biosystems Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy 543 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 1 |
 | Genialis The RNA Biomarker Company. Genialis, the RNA biomarker company, is creating a world where healthcare delivers the best possible outcomes for patients, their families, and their communities. Genialis develops and validates clinically actionable biomarkers informed by the world’s most ethnographically diverse cancer data sets to better predict patient responses and guide treatment decisions for targeted inhibitors, immunotherapies, and other emerging therapeutic classes. Genialis is trusted by pharma and diagnostics partners, and together, we are transforming medicine through data. Data Fusion, Machine Learning, Biomedical Data Analysis, Omics Data Integration, Precision Medicine, Software Development, Data Visualization, Gene Signature, and Predictive Biomarker 9 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Data Analytics | 16 | 43 |
 | DIANA Biotechnologies DIANA Biotechnologies: Diversified Biotech We are leading Czech biotechnology company with a great innovative potential. We focus on the development of products based on our cutting edge research in the fields of molecular diagnostics and drug discovery. We have global ambitions and since our foundation in 2018 we already have achieved some of our goals. During COVID-19 pandemics, we were able to quickly develop one of the most innovative COVID-19 tests worldwide and we helped to increase the testing capacity of the whole country. As a result, we became the biggest Czech manufacturer of RT-PCR tests. Besides RT-PCR, we continue … 59 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology | 3 | 48 |
 | Embleema Embleema is the regulatory-grade health data platform to accelerate new drug discovery and release new treatments sooner Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project … 29 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Blockchain/Cryptocurrency | 10 | 26 |
 | Organovo Holdings, Inc. Discovering drugs using highly customized human tissues as living, dynamic models of human biology and disease. We are pioneering a unique set of therapeutic and drug profiling capabilities based on our revolutionary ability to 3D bioprint tissues that mimic key aspects of human biology and disease. We intend to fundamentally alter the drug discovery landscape by the development of novel therapies for disease which have a much higher chance of efficacy in the clinic focused on human primary cell 3D models of disease that more faithfully recapitulate disease processes. Learn more at www.organovo.com. 3D bioprinting, 3D printing, Drug discovery and … Type: Startup Activities: biotech deeptech Technologies: 3D Printing Synthetic Biology | 0 | 28 |
 | Source BioScience Industry-leading provider of Genomic and Histopathology services, including Cellular & Digital Pathology. Source BioScience, comprised of Source LDPath and Source Genomics, provides industry-leading laboratory services in Genomics and Histopathology, partnering with biotechnology, pharmaceutical, healthcare and academia. Source LDPath provides an end-to-end clinical diagnostic service, from histopathology, including digital pathology and AI, through to molecular diagnostic services. Source LDPath already supports over 85 NHS Trusts and a comprehensive network of Private Healthcare clinics to expand their diagnostic capabilities, ensuring diagnostic results are delivered within clinically actionable timeframes. Source LDPath brings pioneering expertise in digital pathology and AI implementation, helping NHS pathology … 9 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 8 | 199 |
 | Helix Helix is the leading population genomics and precision health organization. We enable health systems, life sciences companies and payers to accelerate the integration of genomic data into patient care and therapeutic development. Learn more at www.helix.com Next Generation Sequencing (NGS), Bioinformatics, Big Data, DNA, Population Health, Population Genomics, Precision Health, Precision Medcine, Exome Sequencing, Medical Research, and Health System Strategy 77 similar entities Type: Startup Activities: healthtech biotech deeptech martech Technologies: Data Analytics | 9 | 548 |
 | Anuva Creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery Anuva is creating the world’s most diverse Genomic Bio/Data Bank to help uncover novel biological pathways for drug discovery. Anuva is a translational research company that is creating the most diverse Genomic Bio/Data Bank of Asian Populations, which is being utilized for research & development within the pharma industry. Our cohorts and biorepository allow for follow-on clinical and translational studies, which greatly empower drug development opportunities. IndiaCHIP, Genomics, Genomics - Emerging markets, Genomics - R&D, Genomics Data Platform, Genomics - India, bioinformatics, and … 65 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology | 8 | 60 |
 | LiveDrop Bio We create all-in-one instruments that make high-throughput single-cell workflows easy thanks to droplet microfluidics At LiveDrop, we develop, build, and sell cutting-edge instruments and methods for high-throughput screening of biological cells and organisms—down to the single-cell level—using microfluidic droplets. Our solutions enable faster, more precise screenings through highly efficient, fully integrated bioassays. LiveDrop’s flagship platform, ModaFlow 4L5C, revolutionises cell screening, drug discovery, and secretome analysis with unparalleled speed and precision. It supports a wide range of applications, including monoclonal antibody discovery, single-cell secretome-based bioassays, high-throughput spheroid manufacturing for drug testing, directed evolution of microbes, and enzyme discovery. We value collaboration … 64 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 4 | 14 |
 | Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world's largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience's expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in … 77 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology | 3 | 576 |
 | Gubra Science of certainty Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (e.g. obesity, diabetes, MASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customers from across … 85 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 6 | 277 |
 | Integrated Biosciences, Inc. Unravelling complex biology with optogenetics, chemistry and computation for small molecule discovery. Our platform is built around a proprietary synthetic biology toolkit, featuring advanced optogenetic tools that enable precise temporal and spatial control of complex pathways and difficult-to-drug targets. Powered by vast proprietary datasets and cutting-edge AI models, our platform accelerates drug discovery and facilitates the generation of novel chemical matter, unlocking solutions for even the most challenging biological systems. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, small molecule, rejuvenation, molecular biology, and novel therapeutics 203 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning | 1 | 10 |
 | Talus Bio Gene regulator profiling in live cells for drug development Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene … 60 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 24 |